| |
NOBORI CLINICAL DATA |
|
• New Generation DES Clinical Evidence |
|
|
| |
|
|
• Nobori Drug Eluting Stent pooled patients level data
Speaker: B. Chevalier |
|
|
| |
NOBORI 1 |
|
Phase 1 Final 5 Years Results
Speaker: B. Chevalier |
|
|
| |
NOBORI 2 |
|
• Very small vessels (≤2.5mm) treated with Nobori drug eluting stent: two years clinical outcome
Speaker: D.Carrié |
|
|
| |
|
|
• Drug eluting stents with biodegradable polymers in acute myocardial infarction
Speaker: F. Fath-Ordoubadi |
|
|
| |
|
|
• Complete revascularisation and clinical outcomes of patients with multivessel disease
Speaker: E.Barbato |
|
|
| |
|
|
• Two years clinical outcomes of diabetic patients treated with a new generation drug-eluting stent
Speaker: M.Wiemer |
|
|
| |
|
|
• Off label use of drug eluting stent with biodegradable polymer at 2 years
Speaker: G.B.Danzi |
|
|
| |
|
|
• Predictive Value of the Charlson Comorbidity Index for Clinical Outcomes After PCI
Speaker: P.Urban |
|
|
| |
|
|
• Challenging bifurcation stenting: two-year clinical outcomes after treatment with a new generation DES
Speaker: A.Serra |
|
|
| |
|
|
• Long term clinical outcome after treatment of restenotic lesions with a new generation
drug eluting stent
Speaker: N.West |
|
|
| |
|
|
• Two years clinical outcomes after treatment of saphenous vein graft with a new generation drug eluting stent
Speaker: R.Wessely |
|
|
| |
|
|
• Long term clinical outcome of patients with chronic total occlusion treated with new generation drug eluting stents
Speaker: B.Chevalier |
|
|
| |
|
|
• Biodegradable polymers, dual antiplatelet therapy and very late stent thrombosis: Review of NOBORI 2 study
Speaker: G.B.Danzi |
|
|
| |
NOBORI 2 |
|
• Safety and Efficacy of Biolimus A9 Eluting stent with Biodegradable Polymer in Real Life NOBORI 2 Trial 12 Months-Primary Endpoint Data.
Speaker: GB Danzi |
|
|
| |
|
|
• Bifurcation stenting with a new generation of drug-eluting stent: 1-year clinical outcome in 600 patients.
Speaker: A. Serra |
|
|
| |
|
|
• One-year clinical outcome in patients with acute myocardial infarction treated with new generation of drug-eluting stents: Nobori AMI study.
Speaker: F. Fath-Ordobadi |
|
|
| |
|
|
• One-year clinical outcomes of patients with coronary chronic total occlusion lesions treated with a newgeneration of drug-eluting stents.
Speaker: B. Chevalier |
|
|
| |
|
|
• Clinical outcome of octogenarians treated with a new generation of drug-eluting stent.
Speaker: G.B. Danzi |
|
|
| |
|
|
• Clinical outcomes of diabetic patients in a large real life setting study of a new drug-eluting stent.
Speaker: M. Wiemer |
|
|
| |
|
|
• Female.
Speaker: F. Mauri-Ferre |
|
|
| |
|
|
• Long Lesion.
Speaker: P. Kala |
|
|
